Citations

Clear

959 citation(s) found for "Service, F J".

243 Relationship Among Granulosa Cell Gnrh-i, -II, and Receptor Mrna Abundance and Follicular Fluid Steroid Hormone Concentrations of Bovine Antral Follicles at Specific Stages of Follicular Development
Northrop‐Albrecht, Emmalee J. , Epperson, Kaitlin M , Zoca, Saulo Menegatti , Perkins, Stephanie D., Daly, Russell F. , Cushman, Robert A. , Rich, Jerica J J , Perry, George A.

Mayo Clinic

Journal of Animal Science | October 8, 2021 | Volume: 99 | Issue: Supplement_3 | Pages: 126-127

10.1093/jas/skab235.230 Get It

Abstract Transcript abundance of two forms of GnRH and its receptor have been characterized in bovine ovaries. The objective was to investigate the relationship of GnRH-1, GnRH-2, GnRH-R, intrafollicular estradiol (E2) and progesterone (P4) during follicular development. Ovaries were collected from beef cows at specific stages of follicular development [pre-selection (PRE, n = 9), post-selection (POST, n = 9), and post-selection 24h after luteal regression (PG, n = 9)]. The largest follicle per stage was aspirated to obtain granulosa cells (GC) and follicular fluid (FF). Total cellular RNA was extracted from GC and RT-PCR was performed for GnRH-1, GnRH-2, GnRH-R and GAPDH. Radioimmunoassays were performed to determine FF concentrations of E2 and P4. Data were analyzed using the MIXED and REG procedures in SAS. There was no difference (P ≥ 0.23) in mRNA abundance of GnRH-2, GnRH-R or FF concentrations of P4 across follicular stages. There was an effect of stage on FF E2 (PRE: 17,925±20,273, POST: 28,458±21,503, and PG: 252,616±21,503 pg/mL; P < 0.01). Stage affected GnRH-1 mRNA abundance (PRE: 2.28±0.55, POST: 0.92±0.55, and PG: 0.11±0.55; P = 0.03). There was no relationship of GnRH-1 and GnRH-2 mRNA abundance or effect of FF P4 on GnRH-R mRNA abundance (P ≥ 0.23). There was no effect of FF P4 on GnRH-1 mRNA abundance (P = 0.68). There was no effect of FF E2 on GnRH-2 mRNA abundance (P = 0.66). As FF E2 increased GnRH-R mRNA abundance tended to increase (P = 0.10;r2=0.13). As FF P4 concentrations increased GnRH-2 mRNA abundance tended to decrease (P = 0.09;r2=0.12). As FF E2 increased GnRH-1 mRNA abundance decreased (P = 0.02;r2=0.20). In conclusion, there were differences in peptide and receptor mRNA abundance of GnRH in relation to FF E2 and P4 at specific stages of follicular development. This is supportive of a regulatory relationship between ovarian GnRH and steroidogenesis. This work is supported by AFRI Grant No.2018-67016-27578 from USDA. USDA is an equal opportunity provider and employer.
235 Uterine Function During Maternal Recognition of Pregnancy Differs Due to Size of the Ovarian Reserve in Beef Heifers
Cushman, Robert A. , Rosasco, Shelby L, Epperson, Kaitlin M , Northrop‐Albrecht, Emmalee J. , Chase, C. C., Snider, Alexandria P , Rich, Jerica J J , Miles, Jeremy R. , Crouse, Matthew S , Perry, George A. , Summers, Adam P.

Mayo Clinic

Journal of Animal Science | October 8, 2021 | Volume: 99 | Issue: Supplement_3 | Pages: 123-123

10.1093/jas/skab235.225 Get It

Abstract The relationship of ovarian reserve parameters to fertility in mammalian females continues to be debated. We demonstrated improved uterine function, creating an environment that is more supportive of early embryonic development in beef heifers with increased numbers of follicles. In the present study we hypothesized that timing of luteolysis differs between heifers with increased compared to heifers with diminished numbers of follicles. Angus heifers (n = 20/ group) were classified as low (14.7 ± 1.1) or high (32 ± 1.1) antral follicle number based on ovarian ultrasonography, and artificially inseminated (d0) following a Select Synch protocol. At d16 after insemination, heifers were slaughtered, and reproductive tracts collected. Tracts were flushed with 20 mL of physiological saline to determine pregnancy status by presence of a conceptus and endometrial samples from the horn ipsilateral to the CL were frozen for determination of transcript abundance. Real-time RT-PCR was performed to determine relative transcript abundance of oxytocin receptor (OXTR) and interferon-stimulated gene-15 (ISG15) with glyceraldehyde-3-phospate dehydrogenase as the endogenous reference gene. Transcript abundance was analyzed using the MIXED procedure of SAS with follicle group, pregnancy status and the interaction as fixed effects. Transcript abundance of ISG15 was greater in pregnant endometrium than non-pregnant endometrium (2.75 ± 0.25 vs 0.16 ± 0.22-fold; P < 0.0001) with no influence of follicle group or the interaction. The interaction of follicle group and pregnancy status influenced OXTR transcript abundance (P = 0.06). Luteolytic mechanisms were activated in non-pregnant heifers with diminished numbers of follicles (1.46 ± 0.25-fold) and were not activated in pregnant heifers (0.06 ± 0.22-fold) or heifers with increased numbers of follicles that were not pregnant (0.32 ± 0.30-fold). These data indicate a wider window of recognition of pregnancy in beef heifers with increased numbers of ovarian follicles. USDA is an equal opportunity provider and employer.
Genome-Wide Association Study of Peripheral Artery Disease
Zuydam, Natalie R. van , Stiby, Alexander, Abdalla, Moustafa , Austin, Erin , McLachlan, Stela , Vlachopoulou, Efthymia, Ahlqvist, Emma , Liao, Chen Di , Sandholm, Niina , Robertson, Neil R., Rayner, Nigel W. , Lindholm, Eero , Sinisalo, Juha , Kallio, Milla , Weiss, Emily , Price, Jackie F. , Paterson, Andrew D. , Klein, Barbara E.K. , Palmer, Colin N.A. , Groop, Per‐Henrik , Groop, Leif , Morris, Andrew P. , Hopewell, Jemma C. , Colhoun, Helen M. , Grétarsdóttir, Sólveig , Þorsteinsdóttir, Unnur , Stefánsson, Kāri , Michael, Mark , Kanninen, Timo, Patrono, Carlo, Nuutila, Pirjo , McKeague, Paul, Steckel-Hamann, Birgit, Gan, Li‐Ming , Nogoceke, Everson, Jablonka, Bernd, Brosnan, Mary-Julia, van Zuydam, Natalie R , Ahlqvist, Emma , Di Liao, Chen , Sandholm, Niina , Forsblom, Carol , Rayner, N William , Lindholm, Eero , Sinisalo, Juha , Perola, Markus , Kallio, Milla , Weiss, Emily , Paterson, Andrew , Salomaa, Veikko , Palmer, Colin N A , McCarthy, Mark I , de Andrade, Mariza , Hopewell, Jemma C , Colhoun, Helen M , Kullo, Iftikhar J , Dahlström, Emma H. , Mahajan, Anubha , McCarthy, Mark I. , Andrade, Mariza de , Kullo, Iftikhar J. , Þorleifsson, Guðmar , Mark, Michael, Thorand, Barbara , Remuzzi, Giuseppe , Dunger, David B. , Shore, Angela C. , Smith, Ulf , Ylä-Herttuala, Seppo , Cobelli, Claudio , Bellazzi, Riccardo , Ferrannini, Ele , Patrono, Carlo, Tortoli, Piero

Mayo Clinic

Circulation: Genomic and Precision Medicine | October 4, 2021 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/circgen.119.002862 | PMID 34601942 Get It

Background: Peripheral artery disease (PAD) affects >200 million people worldwide and is associated with high mortality and morbidity. We sought to identify genomic variants associated with PAD overall and in the contexts of diabetes and smoking status. Methods: We identified genetic variants associated with PAD and then meta-analyzed with published summary statistics from the Million Veterans Program and UK Biobank to replicate their findings. Next, we ran stratified genome-wide association analysis in ever smokers, never smokers, individuals with diabetes, and individuals with no history of diabetes and corresponding interaction analyses, to identify variants that modify the risk of PAD by diabetic or smoking status. Results: We identified 5 genome-wide significant ( P association ≤5×10 −8 ) associations with PAD in 449 548 (N cases =12 086) individuals of European ancestry near LPA (lipoprotein [a]), CDKN2BAS1 (CDKN2B antisense RNA 1), SH2B3 (SH2B adaptor protein 3) - PTPN11 (protein tyrosine phosphatase non-receptor type 11), HDAC9 (histone deacetylase 9), and CHRNA3 (cholinergic receptor nicotinic alpha 3 subunit ) loci (which overlapped previously reported associations). Meta-analysis with variants previously associated with PAD showed that 18 of 19 published variants remained genome-wide significant. In individuals with diabetes, rs116405693 at the CCSER1 (coiled-coil serine rich protein 1 ) locus was associated with PAD (odds ratio [95% CI], 1.51 [1.32–1.74], P diabetes =2.5×10 −9 , P interactionwithdiabetes =5.3×10 −7 ). Furthermore, in smokers, rs12910984 at the CHRNA3 locus was associated with PAD (odds ratio [95% CI], 1.15 [1.11–1.19], P smokers =9.3×10 −10 , P interactionwithsmoking =3.9×10 −5 ). Conclusions: Our analyses confirm the published genetic associations with PAD and identify novel variants that may influence susceptibility to PAD in the context of diabetes or smoking status.
Effects of Intermittent Pneumatic Compression on Lower Limb Lymphedema in Patients with Type 2 Diabetes Mellitus: A Pilot Randomized Controlled Trial
Sire, Alessandro de , Inzitari, Maria Teresa , Moggio, Lucrezia , Sire, Giustino de, Supervía, Marta , Petraroli, Annalisa , Rubino, Mariangela , Carbotti, Delia Francesca, Succurro, Elena , Ammendolia, Antonio , Andreozzi, Francesco , de Sire, Alessandro , Succurro, Elena , Ammendolia, Antonio , Andreozzi, Francesco , Pinto, Monica

Mayo Clinic

Medicina | September 27, 2021 | Volume: 57 | Issue: 10 | Pages: 1018

10.3390/medicina57101018 | PMID 34684055 Get It

Background and Objectives: Diabetes mellitus type 2 (T2DM) is a chronic disease associated with fluid accumulation in the interstitial tissue. Manual lymphatic drainage (MLD) plays a role in reducing lymphoedema, like intermittent pneumatic compression (IPC). By the present pilot study, we aimed to evaluate the efficacy of a synergistic treatment with MLD and IPC in reducing lower limb lymphedema in T2DM patients. Materials and Methods: Adults with a clinical diagnosis of T2DM and lower limb lymphedema (stage II–IV) were recruited from July to December 2020. Study participants were randomized into two groups: experimental group, undergoing a 1-month rehabilitative program consisting of MLD and IPC (with a compression of 60 to 80 mmHg); control group, undergoing MLD and a sham IPC (with compression of <30 mmHg). The primary outcome was the lower limb lymphedema reduction, assessed by the circumferential method (CM). Secondary outcomes were: passive range of motion (pROM) of hip, knee, and ankle; quality of life; laboratory exams as fasting plasma glucose and HbA1c. At baseline (T0) and at the end of the 1-month rehabilitative treatment (T1), all the outcome measures were assessed, except for the Hb1Ac evaluated after three months. Results: Out of 66 T2DM patients recruited, only 30 respected the eligibility criteria and were randomly allocated into 2 groups: experimental group (n = 15; mean age: 54.2 ± 4.9 years) and control group (n = 15; mean age: 54.0 ± 5.5 years). At the intra-group analysis, the experimental group showed a statistically significant improvement of all outcome measures (p < 0.05). The between-group analysis showed a statistically significant improvement in pROM of the hip, knee, ankle, EQ-VAS, and EQ5D3L index at T1. Conclusions: A multimodal approach consisting of IPC and MLD showed to play a role in reducing lower limb lymphedema, with an increase of pROM and HRQoL. Since these are preliminary data, further studies are needed.
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
Ernst, Moritz , Oeser, Annika , Besiroglu, Burcu, Caro-Valenzuela, Julia , Aziz, Mohamed Abd El, Monsef, Ina , Borchmann, Peter , Estcourt, Lise J , Goldkuhle, Marius , Abd El Aziz, Mohamed, Skoetz, Nicole

Mayo Clinic

Cochrane Database of Systematic Reviews | September 13, 2021 | Volume: 2021 | Issue: 9 | Pages: No page available

10.1002/14651858.cd013365.pub2 | PMID 34515338 Get It

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
Herrmann, Joerg , Lenihan, Daniel J. , Armenian, Saro H. , Barac, Ana , Blaes, Anne , Cardinale, Daniela , Carver, Joseph R. , Dent, Susan , Ky, Bonnie , Lyon, Alexander R. , Fradley, Michael G. , Ganatra, Sarju , Curigliano, Giuseppe , Mitchell, Joshua D. , Minotti, Giorgio , Lang, Ninian N. , Liu, Jennifer E. , Neilan, Tomas G. , O’Quinn, Rupal, Pusic, Iskra , Porter, Charles , Reynolds, Kerry L. , Ruddy, Kathryn J. , Valent, Peter , Lenihan, Daniel , Armenian, Saro H , Carver, Joseph , López-Fernández, Teresa , Fradley, Michael G , Ganatra, Sarju , Curigliano, Giuseppe , Mitchell, Joshua D , Minotti, Giorgio , Lang, Ninian N , Nohria, Anju , Porter, Charles , Thavendiranathan, Paaladinesh , Barac, Ana , Blaes, Anne H , Ky, Bonnie , Valent, Peter , Lyon, Alexander R , López‐Fernández, Teresa , Dent, Susan

Mayo Clinic

European Heart Journal | September 10, 2021 | Volume: 43 | Issue: 4 | Pages: 280-299

10.1093/eurheartj/ehab674 | PMID 34904661 Get It

Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the most commonly reported CV toxicities, including cardiomyopathy/heart failure and myocarditis, vascular toxicity, and hypertension, as well as arrhythmias and QTc prolongation. The current document reflects a harmonizing review of the current landscape in CV toxicities and the definitions used to define these. This consensus effort aims to provide a structure for definitions of CV toxicity in the clinic and for future research. It will be important to link the definitions outlined herein to outcomes in clinical practice and CV endpoints in clinical trials. It should facilitate communication across various disciplines to improve clinical outcomes for cancer patients with CV diseases.
Application of artificial intelligence to the electrocardiogram
Attia, Zachi I. , Harmon, David , Behr, Elijah R. , Friedman, Paul A. , Harmon, David M , Behr, Elijah Raphael , Attia, Zachi I

Mayo Clinic

European Heart Journal | September 8, 2021 | Volume: 42 | Issue: 46 | Pages: 4717-4730

10.1093/eurheartj/ehab649 | PMID 34534279 Get It

Abstract Artificial intelligence (AI) has given the electrocardiogram (ECG) and clinicians reading them super-human diagnostic abilities. Trained without hard-coded rules by finding often subclinical patterns in huge datasets, AI transforms the ECG, a ubiquitous, non-invasive cardiac test that is integrated into practice workflows, into a screening tool and predictor of cardiac and non-cardiac diseases, often in asymptomatic individuals. This review describes the mathematical background behind supervised AI algorithms, and discusses selected AI ECG cardiac screening algorithms including those for the detection of left ventricular dysfunction, episodic atrial fibrillation from a tracing recorded during normal sinus rhythm, and other structural and valvular diseases. The ability to learn from big data sets, without the need to understand the biological mechanism, has created opportunities for detecting non-cardiac diseases as COVID-19 and introduced challenges with regards to data privacy. Like all medical tests, the AI ECG must be carefully vetted and validated in real-world clinical environments. Finally, with mobile form factors that allow acquisition of medical-grade ECGs from smartphones and wearables, the use of AI may enable massive scalability to democratize healthcare.
Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and International Stereotactic Radiosurgery Society practice recommendations
Mathieu, David, Kotecha, Rupesh, Sahgal, Arjun, Salles, Antonio De, Fariselli, Laura, Pollock, Bruce E., Levivier, Marc, Ma, Lijun, Paddick, Ian, Regis, Jean, Yomo, Shoji, Suh, John H., Rubens, Muni, Sheehan, Jason P., Mathieu, David , Rubens, Muni , Yomo, Shoji , Mathieu, David , Kotecha, Rupesh, Sahgal, Arjun, Salles, Antonio De, Fariselli, Laura, Pollock, Bruce E., Levivier, Marc, Ma, Lijun, Paddick, Ian, Regis, Jean, Suh, John H., Sheehan, Jason P.

Mayo Clinic

Journal of Neurosurgery | September 3, 2021 | Volume: 136 | Issue: 3 | Pages: 801-812

10.3171/2021.2.jns204440 | PMID 34479203 Get It

OBJECTIVE A systematic review was performed to provide objective evidence on the use of stereotactic radiosurgery (SRS) in the management of secretory pituitary adenomas and develop consensus recommendations. METHODS The authors performed a systematic review of the English-language literature up until June 2018 using the PRISMA guidelines. The PubMed (Medline), Embase, and Cochrane databases were searched. A total of 45 articles reporting single-institution outcomes of SRS for acromegaly, Cushing’s disease, and prolactinomas were selected and included in the analysis. RESULTS For acromegaly, random effects meta-analysis estimates for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rates were 97.0% (95% CI 96.0%–98.0%), 44.0% (95% CI 35.0%–53.0%), and 17.0% (95% CI 13.0%–23.0%), respectively. For Cushing’s disease, random effects estimates for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rate were 92.0% (95% CI 87.0%–95.0%), 48.0% (95% CI 35.0%–61.0%), and 21.0% (95% CI 13.0%–31.0%), respectively. For prolactinomas, random effects estimates for crude tumor control rate, crude endocrine remission rate, and any new hypopituitarism rate were 93.0% (95% CI 90.0%–95.0%), 28.0% (95% CI 19.0%–39.0%), and 12.0% (95% CI 6.0%–24.0%), respectively. Meta-regression analysis did not show a statistically significant association between mean margin dose with crude endocrine remission rate or mean margin dose with development of any new hypopituitarism rate for any of the secretory subtypes. CONCLUSIONS SRS offers effective tumor control of hormone-producing pituitary adenomas in the majority of patients but a lower rate of endocrine improvement or remission.
Hospital transfusion service operations during the SARS‐CoV‐2 pandemic: Lessons learned from the AABB hospital survey in preparation for the next infectious disease outbreak
Rajbhandary, Srijana , Shmookler, Aaron , Cohn, Claudia S. , Nunes, Eduardo, Karafin, Matthew S. , Stubbs, James R. , Pagano, Monica B. , Stubbs, James R , Cohn, Claudia S , Pagano, Monica B

Mayo Clinic

Transfusion | September 1, 2021 | Volume: 61 | Issue: 11 | Pages: 3129-3138

10.1111/trf.16643 | PMID 34469010 Get It

AbstractBackgroundThe SARS‐CoV‐2 pandemic disrupted hospital operations, affected the blood supply, and challenged the health care system to develop new therapeutic options, including convalescent plasma (CCP). The aim of this study is to describe and analyze blood supply fluctuations and the use of convalescent plasma in 2020.MethodsAABB distributed a weekly and biweekly questionnaire through email to hospital‐based members (HBM).ResultsThe survey was sent to 887 HBM with 479 unique respondents, most of the hospitals served pediatric and adult patients, and all states of the country participated, except Idaho and Vermont. Fifty four percent of HBM reported increased wastage in the early phase of the pandemic (May), which decreased to 4% by the end of June and throughout the rest of the year. The majority of HBM reported receiving alerts from their blood suppliers reporting blood shortages throughout the year. During March and April, only 12% of HBM were performing elective surgical procedures. The top reasons to delay procedures were: bed availability (28%); COVID‐19 caseload (23%; and blood availability (19%). By mid‐April, 42% HBM had transfused CCP and reported >24 h delay in getting the units; the vast majority obtained CCP using the Expanded Access Protocol, and later, the Emergency Use Authorization. HBM consistently prioritized the most severe patients to receive CCP, but the proportion of severely ill recipients fell from 52% to 37% between May and October, with an increase from 5% to 21% of HBM providing CCP transfusion early in the course of the disease.DiscussionBlood utilization and availability fluctuated during the pandemic. The fluctuations appeared to be related to the number of COVID‐19 in the community. The use and regulatory landscape of CCP rapidly evolved over the first 8 months of the pandemic.